查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014906

液态生物检体市场：按生物标记、检体、类型、技术、适应症、最终用户和应用划分——2026-2032年全球市场预测

Liquid Biopsy Market by Biomarkers, Sample, Type, Technology, Indication, End-User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，液态生物检体市场价值将达到 75.2 亿美元，到 2026 年将成长至 84.4 亿美元，到 2032 年将达到 173.1 亿美元，复合年增长率为 12.63%。

主要市场统计数据
基准年 2025 75.2亿美元
预计年份：2026年 84.4亿美元
预测年份 2032 173.1亿美元
复合年增长率 (%) 12.63%

为产业相关人员权威介绍液态生物检体和精准医疗/肿瘤诊断的变革潜力。

液态生物检体是诊断医学领域的模式转移，它透过分析体液中的循环生物标记物，提供了一种侵入性较小的途径来了解肿瘤的生物学特征。与需要手术切除且有相关风险的传统切片检查不同，液态生物检体利用循环肿瘤DNA、细胞和囊泡来即时获取动态分子资讯。这种方法与日益兴起的「精准肿瘤学」理念相契合，精准肿瘤学可以透过优化治疗方案以匹配个别分子特征，从而显着改善患者的治疗效果。

探索透过技术突破、监管进步和策略性产业合作，重新定义液态生物检体格局的关键变化。

在次世代定序、数位PCR和新型生物资讯流程等突破性技术的推动下，液态切片领域正以前所未有的速度发展。这些技术进步显着提高了分析物的检测敏感度和特异性，使得在癌症早期阶段识别罕见的循环肿瘤DNA片段成为可能。同时，主要市场的监管机构也开始实施更有效率的伴随诊断核准流程，这反映了他们对液态切片检测的临床效用和可重复性的信心。

评估 2025 年美国关税对液态生物检体供应链、定价结构和全球研究合作的累积影响。

2025年1月1日，美国对进口诊断剂和设备加征新关税，加剧了跨境供应链的复杂性。新增关税提高了关键耗材的接收成本，迫使製造商和实验室合作伙伴重新评估其筹资策略和库存模式。对于依赖专用试剂的公司而言，寻找国内替代供应商并签订长期合约已成为维持利润率和避免服务中断的关键挑战。

透过多方面的细分，包括生物标记、检体、检测类型、技术、适应症、应用和最终用户趋势，可以获得关键见解。

基于生物标记分类的分割揭示了成熟分析物和新兴分析物之间的相互作用。游离细胞DNA (cfDNA) 因其与肿瘤负荷和突变谱的明确相关性，仍是临床检测的基础。同时，循环性肿瘤细胞(CTC) 为表型分析开启了新的机会。循环肿瘤DNA (ctDNA) 技术的出现使得即时监测抗药性突变成为可能，而对细胞外囊泡 (EV) 的研究则为RNA转运和蛋白质组学特征的研究开闢了新的领域。

了解影响美洲、欧洲、中东和非洲以及亚太市场液态生物检体引入和创新的区域趋势。

美洲地区凭藉其先进的法规结构和大规模的临床应用，继续发挥主导作用。各国政府针对癌症筛检和价值医疗的倡议，正在加速推进保险报销方面的讨论，并推动大学医院和社区医院更广泛地应用相关技术。此外，本地诊断公司与国际技术供应商之间的策略合作，正在加强供应链，并扩大区域内尖端检测技术的普及范围。

本分析考察了快速发展的液态生物检体生态系统中主要企业的策略定位、竞争力和市场贡献。

领先的诊断和生物技术公司正透过差异化的平台、策略性收购和广泛的智慧财产权组合来巩固其市场地位。拥有完善检测网路的成熟公司正利用丰富的临床检验数据来拓展其检测服务，而纯粹的创新者则专注于独特的化学技术和先进的生物资讯学，以期抢占市场先机。

制定具有前瞻性的策略和可操作的建议，使行业相关人员能够充分利用液态生物检体的进步和市场机会。

为了应对不断变化的液态生物检体领域，行业相关人员应优先投资于灵活的检测架构，以支援靶向和广谱检测应用。这种方法能够灵活应对新出现的生物标记和监管政策的变化。将多组体学功能整合到现有工作流程中，可以提高诊断准确性，并更深入了解肿瘤异质性。

概述了严格的调查方法，包括数据收集、分析和检验，以全面涵盖液态生物检体领域。

为确保报告的可靠性和可信度，本报告采用了严格的一手和二手调查方法相结合的方式。首先，我们进行了广泛的二手研究，涵盖同行评审期刊、临床试验註册资讯、专利申请、监管文件和白皮书，从而为技术和临床理解奠定了全面的基础。

本文总结了液态生物检体创新在推进精准诊断和患者照护的策略意义、未来前景和永续价值。

液态生物检体已成为现代诊断实践的基石，弥合了分子层面洞察与个人化患者管理之间的鸿沟。它能够透过非侵入性取样检测和监测疾病，为早期疗育、优化治疗和长期后续观察开闢了新的途径。随着技术平台的日趋成熟，液态生物检体正从小众研究应用转向主流临床应用。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按生物标记分類的液态生物检体市场

  • 细胞中的游离DNA
  • 循环性肿瘤细胞
  • 循环肿瘤DNA
  • 细胞外囊泡

第九章 按检体类型分類的液态生物检体市场

  • 血液衍生的
  • 尿液来源的

第十章：液态生物检体市场：按类型划分

  • 检测试剂盒
  • 装置
  • 服务

第十一章：液态生物检体市场：依技术划分

  • 利用NGS进行多基因平行分析
  • 利用PCR微阵列进行单一基因分析

第十二章：液态生物检体市场：依适应症划分

  • 癌症治疗
    • 乳癌
    • 结肠癌
    • 肺癌
    • 恶性黑色素瘤
    • 摄护腺癌
  • 非癌症适应症

第十三章：液态生物检体市场：依最终用户划分

  • 学术和研究机构
  • 临床诊断检查室
  • 医院
  • 临床检查室

第十四章：液态生物检体市场：依应用领域划分

  • 早期癌症筛检
  • 復发监测
  • 治疗方法方案
  • 治疗监测

第十五章：液态生物检体市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：液态生物检体市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章：液态生物检体市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国液态生物检体市场

第十九章：中国液态生物检体市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ANGLE PLC
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biocartis NV
  • Danaher Corporation
  • DiaCarta, Inc.
  • Dxcover Limited
  • Epic Sciences Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GENCURIX
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Labcorp Holdings Inc.
  • Laboratory Dr. med. Pachmann
  • Lucence Health Inc.
  • LungLife AI, Inc.
  • MDxHealth SA
  • Menarini Silicon Biosystems SpA
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • OncoDNA SA
  • PerkinElmer, Inc.
  • Personalis, Inc.
  • QIAGEN NV
  • SAGA Diagnostics AB
  • Strand Life Sciences Pvt Ltd.
  • Sysmex Corporation
  • Tempus AI, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-43470FC608C8

The Liquid Biopsy Market was valued at USD 7.52 billion in 2025 and is projected to grow to USD 8.44 billion in 2026, with a CAGR of 12.63%, reaching USD 17.31 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.52 billion
Estimated Year [2026] USD 8.44 billion
Forecast Year [2032] USD 17.31 billion
CAGR (%) 12.63%

An authoritative introduction to liquid biopsy and its transformative potential in precision medicine and oncology diagnostics for industry stakeholders

Liquid biopsy represents a paradigm shift in diagnostic medicine by offering a minimally invasive window into tumor biology through the analysis of circulating biomarkers in bodily fluids. Unlike conventional tissue biopsies that necessitate surgical extraction and carry procedural risks, liquid biopsy harnesses circulating tumor DNA, cells, and vesicles to capture dynamic molecular information in real time. This approach aligns with the growing emphasis on precision oncology, where tailoring therapeutic regimens to individual molecular profiles can dramatically improve patient outcomes.

As cancer incidence continues to rise globally, healthcare systems are under pressure to deliver cost-effective, rapid diagnostics that minimize patient discomfort without compromising accuracy. Liquid biopsy addresses these demands by enabling serial monitoring of disease progression, early detection of minimal residual disease, and the identification of actionable mutations that guide targeted therapies. Moreover, its application extends beyond oncology into transplant medicine, prenatal screening, and infectious disease monitoring, positioning liquid biopsy as a versatile tool for modern clinical practice.

Stakeholders across pharmaceutical, diagnostic, and research sectors are now evaluating how to integrate liquid biopsy into existing workflows and regulatory pathways. With technological advances driving down assay time and costs, liquid biopsy is poised to become a standard component of patient management. In the following sections, we explore the transformative forces reshaping this landscape, the implications of recent policy changes, and the strategic insights that will guide industry leaders forward.

Exploring the pivotal shifts redefining the liquid biopsy landscape through technological breakthroughs regulatory progress and strategic industry collaborations

The liquid biopsy landscape is evolving at an unprecedented pace, propelled by breakthroughs in next-generation sequencing, digital PCR, and novel bioinformatics pipelines. These technological advancements have significantly increased the sensitivity and specificity of analyte detection, enabling the identification of rare circulating tumor DNA fragments at early stages of cancer. Concurrently, regulatory agencies across key markets have begun to issue more streamlined approval pathways for companion diagnostics, reflecting confidence in the clinical utility and reproducibility of liquid biopsy assays.

At the same time, strategic collaborations between diagnostic manufacturers, academic centers, and pharmaceutical firms are accelerating assay validation and broadening the scope of clinical studies. Such partnerships are fostering the co-development of targeted panels aligned with emerging targeted therapies, thereby integrating diagnostics directly into the drug development lifecycle. Meanwhile, decentralized testing models-ranging from point-of-care platforms to patient-collected sampling kits-are democratizing access and supporting remote monitoring initiatives.

Collectively, these forces are redefining the competitive dynamics of the liquid biopsy domain. Incumbent laboratory providers are investing in proprietary platforms to maintain differentiation, while nimble start-ups continue to innovate assay chemistries and data analytics. Looking ahead, convergence around multi-omics integration and standardized reporting frameworks will further solidify liquid biopsy's role as a cornerstone of personalized care.

Assessing the cumulative repercussions of the 2025 United States tariffs on liquid biopsy supply chains pricing structures and global research collaborations

On January 1, 2025, new U.S. tariffs on imported diagnostic reagents and instrumentation took effect, introducing a layer of complexity for cross-border supply chains. The added duties have increased landed costs for core consumables, prompting manufacturers and laboratory partners to reassess sourcing strategies and inventory models. For companies reliant on specialized reagents, securing alternative domestic suppliers or negotiating long-term contracts has become a critical objective to contain margins and avoid service disruptions.

The ripple effects extend into pricing structures, as laboratories pass incremental expenses to payers and patients, potentially impacting adoption rates in price-sensitive segments. To mitigate these pressures, several industry players have begun exploring localized manufacturing solutions, including establishing regional production hubs and partnering with contract development organizations. In parallel, increased collaboration with customs authorities and trade associations has enabled more efficient classification and duty minimization, offering relief to stakeholders navigating the evolving tariff landscape.

Despite these headwinds, many organizations view the 2025 tariffs as a catalyst to strengthen domestic supply resilience and foster innovation in reagent design. By investing in robust regional capabilities and diversifying supplier networks, the industry anticipates a more balanced cost structure over the long term, ultimately supporting sustainable growth and uninterrupted patient access.

Deriving critical insights from multifaceted segmentation of biomarkers samples assay types technologies indications applications and end-user dynamics

Segmentation by biomarker class reveals the interplay between mature and emerging analytes. Cell-free DNA continues to anchor clinical assays due to its well-established correlation with tumor burden and mutational profiling, while circulating tumor cells unlock opportunities for phenotypic analysis. The advent of circulating tumor DNA technologies enables real-time monitoring of resistance mutations, and the exploration of extracellular vesicles is opening new research frontiers around RNA cargo and proteomic signatures.

When considering sample origin, blood-based tests dominate current workflows because of established venipuncture protocols and high analyte yield. However, urine-based assays are gaining traction as a noninvasive alternative for longitudinal screening, particularly in urological and genitourinary indications. Advances in sample stabilization and extraction methods are narrowing performance gaps, setting the stage for wider clinical adoption of diversified fluid matrices.

In terms of product taxonomy, assay kits form the backbone of commercial offerings by delivering standardized workflows that simplify laboratory implementation. Instruments add value through automation and throughput optimization, while services encompass bespoke assay development, data interpretation, and clinical reporting. On the technology front, multi-gene parallel analysis using next-generation sequencing is prized for its multiplexing capacity and depth of coverage, whereas single-gene analysis via PCR microarrays maintains a strong presence in targeted mutation detection due to rapid turnaround.

Indication-driven segmentation underscores the primacy of cancer applications, with breast, colorectal, lung, melanoma, and prostate cancers accounting for the majority of clinical validation studies. Non-cancer indications are expanding into areas such as organ transplant rejection monitoring and prenatal aneuploidy screening. Among end-users, academic and research centers spearhead exploratory studies, while clinical diagnostic laboratories, hospitals, and physician office labs drive routine testing volumes. Finally, application segmentation reveals a balanced portfolio of early cancer screening initiatives, recurrence monitoring protocols, therapy selection assays, and treatment monitoring programs, reflecting the multifaceted utility of liquid biopsy in patient management.

Uncovering regional dynamics shaping liquid biopsy adoption and innovation across the Americas Europe Middle East Africa and Asia Pacific markets

The Americas continue to lead with advanced regulatory frameworks and high-volume clinical adoption. Government initiatives focusing on cancer screening and value-based care have accelerated reimbursement discussions, enabling broader uptake in both academic medical centers and community hospitals. Moreover, strategic partnerships between local diagnostic companies and international technology providers have fortified supply chains and expanded regional access to cutting-edge assays.

Europe, Middle East, and Africa present a heterogeneous landscape marked by diverse regulatory regimes and reimbursement environments. In Western Europe, centralized health technology assessments and national screening programs drive standardization, whereas emerging markets in Eastern Europe, the Middle East, and Africa are gradually integrating liquid biopsy into oncology networks through pilot projects and center-of-excellence collaborations. Cross-border data sharing and harmonized clinical guidelines remain key enablers of sustainable growth across these jurisdictions.

Asia-Pacific is characterized by rapid market expansion underpinned by significant public health investments and rising cancer incidence. Government funding for cancer genomics and domestic manufacturing incentives have catalyzed indigenous assay development. Collaborative research between regional academic institutions and global diagnostic firms is intensifying, while the rollout of digital pathology and telemedicine platforms supports remote sample collection and result dissemination, extending the reach of liquid biopsy solutions.

Analyzing strategic positioning competitive strengths and market contributions of leading corporations in the rapidly evolving liquid biopsy ecosystem

Leading diagnostic and biotechnology companies are positioning themselves through differentiated platforms, strategic acquisitions, and expansive intellectual property portfolios. Legacy players with established laboratory networks are leveraging deep clinical validation data to extend their assay menus, while pure-play innovators focus on proprietary chemistries and advanced bioinformatics to achieve early market entry.

Collaborative alliances between pharmaceutical companies and diagnostic developers are accelerating the co-development of companion diagnostics tailored to specific targeted therapies. Start-ups are forging partnerships with contract research organizations to streamline multicenter clinical trials, ensuring robust evidence generation and regulatory alignment. At the same time, instrument manufacturers are integrating connectivity features and cloud-based data analytics into their platforms, enhancing operational efficiency and facilitating seamless integration with laboratory information systems.

Beyond technology differentiation, corporate strategies are increasingly oriented toward geographic expansion through regional sales networks and production hubs. By aligning global R&D pipelines with localized commercialization strategies, leading companies are building scalable models that address diverse regulatory requirements and market access challenges.

Crafting forward-looking strategies and practical recommendations for industry stakeholders to capitalize on liquid biopsy advancements and market opportunities

To navigate the evolving liquid biopsy environment, industry stakeholders should prioritize investment in flexible assay architectures that support both targeted and broad-panel applications. This approach ensures agility in responding to emerging biomarkers and regulatory shifts. Integrating multi-omics capabilities into existing workflows will enhance diagnostic accuracy and provide richer insights into tumor heterogeneity.

Building resilient supply chains through regional manufacturing partnerships and dual-sourcing agreements can mitigate exposure to trade policy fluctuations. Organizations should also establish cross-functional teams that unite regulatory, commercial, and scientific experts to streamline product approvals and reimbursement negotiations. Collaborative initiatives with payers and healthcare providers will strengthen the value proposition by demonstrating real-world clinical utility and cost savings.

Digital transformation should remain a strategic priority, with investments in cloud-native analytics, artificial intelligence-driven variant interpretation, and telehealth-enabled sample collection. These technologies will support decentralized testing models and personalized patient engagement. Finally, fostering open innovation through consortiums and public-private partnerships will accelerate the validation of novel analytes and drive the harmonization of reporting standards, reinforcing liquid biopsy's role in precision medicine.

Outlining rigorous research methodology encompassing data collection analysis validation to ensure comprehensive coverage of the liquid biopsy domain

This report's methodology integrates a rigorous blend of secondary and primary research to ensure robustness and credibility. Initially, extensive secondary research was conducted, encompassing peer-reviewed journals, clinical trial registries, patent filings, regulatory publications, and white papers to establish a comprehensive foundation of technical and clinical understanding.

Primary research was conducted through in-depth interviews with senior executives, laboratory directors, and key opinion leaders across diagnostics, pharmaceutical, and academic sectors. These expert dialogues provided nuanced perspectives on assay development, regulatory strategy, and commercialization challenges. Data triangulation techniques validated qualitative insights against proprietary databases and financial disclosures to reinforce accuracy.

Quantitative analysis involved mapping product pipelines, technology adoption metrics, and regional deployment patterns. Key variables were cross-referenced with public health statistics and reimbursement schedules to contextualize application potential. Validation workshops with external advisors and technical specialists were organized to resolve discrepancies and refine assumptions.

Collectively, this multi-layered approach delivers a holistic view of the liquid biopsy domain, balancing empirical evidence with expert interpretation to guide strategic decision-making.

Summarizing the strategic significance future outlook and enduring value of liquid biopsy innovations for advancing precision diagnostics and patient care

Liquid biopsy has emerged as a cornerstone of modern diagnostic practice, bridging the gap between molecular insights and personalized patient management. Its capacity to detect and monitor disease through noninvasive sampling unlocks new avenues for early intervention, treatment optimization, and long-term surveillance. As technology platforms mature, liquid biopsy is transitioning from niche research applications to mainstream clinical adoption.

Strategically, stakeholders who align their portfolios with the evolving landscape-incorporating flexible assay designs, resilient supply chains, and digital innovation-will be best positioned to capitalize on market opportunities. Continued collaboration across industry, academia, and regulatory bodies will drive the standardization of workflows and reimbursement frameworks, further reducing barriers to implementation.

Looking ahead, the integration of liquid biopsy with complementary diagnostics and therapeutic modalities promises to accelerate the shift toward truly individualized medicine. By embracing a data-driven, patient-centered approach, industry leaders can unlock significant clinical and commercial value, reinforcing liquid biopsy's role as a transformative force in healthcare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liquid Biopsy Market, by Biomarkers

  • 8.1. Cell-free DNA
  • 8.2. Circulating Tumor Cells
  • 8.3. Circulating Tumor DNA
  • 8.4. Extracellular Vesicles

9. Liquid Biopsy Market, by Sample

  • 9.1. Blood Based
  • 9.2. Urine Based

10. Liquid Biopsy Market, by Type

  • 10.1. Assay Kits
  • 10.2. Instruments
  • 10.3. Services

11. Liquid Biopsy Market, by Technology

  • 11.1. Multi-gene Parallel Analysis using NGS
  • 11.2. Single-gene Analysis using PCR Microarrays

12. Liquid Biopsy Market, by Indication

  • 12.1. Cancer Indication
    • 12.1.1. Breast Cancer
    • 12.1.2. Colorectal Cancer
    • 12.1.3. Lung Cancer
    • 12.1.4. Melanoma
    • 12.1.5. Prostate Cancer
  • 12.2. Non-Cancer Indication

13. Liquid Biopsy Market, by End-User

  • 13.1. Academic & Research Centers
  • 13.2. Clinical Diagnostic Laboratories
  • 13.3. Hospitals
  • 13.4. Physician's Office Laboratories

14. Liquid Biopsy Market, by Application

  • 14.1. Early Cancer Screening
  • 14.2. Recurrence Monitoring
  • 14.3. Therapy Selection
  • 14.4. Treatment Monitoring

15. Liquid Biopsy Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Liquid Biopsy Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Liquid Biopsy Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Liquid Biopsy Market

19. China Liquid Biopsy Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. ANGLE PLC
  • 20.6. Bio-Rad Laboratories, Inc.
  • 20.7. Bio-Techne Corporation
  • 20.8. Biocartis NV
  • 20.9. Danaher Corporation
  • 20.10. DiaCarta, Inc.
  • 20.11. Dxcover Limited
  • 20.12. Epic Sciences Inc.
  • 20.13. Exact Sciences Corporation
  • 20.14. F. Hoffmann-La Roche Ltd.
  • 20.15. GENCURIX
  • 20.16. Guardant Health, Inc.
  • 20.17. Illumina, Inc.
  • 20.18. Labcorp Holdings Inc.
  • 20.19. Laboratory Dr. med. Pachmann
  • 20.20. Lucence Health Inc.
  • 20.21. LungLife AI, Inc.
  • 20.22. MDxHealth SA
  • 20.23. Menarini Silicon Biosystems SpA
  • 20.24. Merck KGaA
  • 20.25. Myriad Genetics, Inc.
  • 20.26. Natera, Inc.
  • 20.27. NeoGenomics Laboratories, Inc.
  • 20.28. OncoDNA SA
  • 20.29. PerkinElmer, Inc.
  • 20.30. Personalis, Inc.
  • 20.31. QIAGEN N.V.
  • 20.32. SAGA Diagnostics AB
  • 20.33. Strand Life Sciences Pvt Ltd.
  • 20.34. Sysmex Corporation
  • 20.35. Tempus AI, Inc.
  • 20.36. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BLOOD BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BLOOD BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BLOOD BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIQUID BIOPSY MARKET SIZE, BY URINE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LIQUID BIOPSY MARKET SIZE, BY URINE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIQUID BIOPSY MARKET SIZE, BY URINE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MULTI-GENE PARALLEL ANALYSIS USING NGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LIQUID BIOPSY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIQUID BIOPSY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LIQUID BIOPSY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIQUID BIOPSY MARKET SIZE, BY NON-CANCER INDICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LIQUID BIOPSY MARKET SIZE, BY NON-CANCER INDICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIQUID BIOPSY MARKET SIZE, BY NON-CANCER INDICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PHYSICIAN'S OFFICE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PHYSICIAN'S OFFICE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PHYSICIAN'S OFFICE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LIQUID BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIQUID BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LIQUID BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. GCC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 173. GCC LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. GCC LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. GCC LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 179. GCC LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. G7 LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 200. G7 LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. G7 LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. G7 LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 206. G7 LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. NATO LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 209. NATO LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 210. NATO LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. NATO LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. NATO LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. NATO LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)